Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: Andrew T who wrote (477)	3/3/1998 9:27:00 AM
From: Shadow	Read Replies (1) \| Respond to of 4650

NEWS!!! New Lung Cancer Treatment Part of Proprietary Technology Reported by Advanced Optics Electronics Inc. March 3, 1998 09:04 AM ALBUQUERQUE, N.M.--(BUSINESS WIRE)--March 3, 1998--Advanced Optics Electronics, Inc. ADOT , today reported that Biomoda, Inc. (a bio-technology company in which Advanced Optics has a significant minority interest) has announced the completion of an advanced proprietary imaging and treatment program for lung cancer. This treatment was developed concurrently with the early cancer detection test announced by Advanced Optics on February 25. Research on both the early cancer detection test and the proprietary imaging and treatment program was conducted at Los Alamos National Laboratories in New Mexico, the University of New Mexico at Albuquerque, and St. Mary's Hospital and Medical Center in Grand Junction, Colorado. Biomoda, Inc.'s research scientists, in conjunction with the University of California, have adapted their patented molecular marker/binder technology (utilized to create the earliest cancer detection test available) to generate this uniquely integrated treatment for lung cancer. The early detection cancer test can be expected to improve 5-year survival rates from at least 13% to 46%. With the advent of Biomoda's new lung cancer treatment, this diagnostic/treatment program can be expected to increase these survival rates even further. Public testing of this research will soon begin at a respected cytopathology lab in Scottsdale, Ariz. This press release contains forward-looking statements with respect to the results of operations and business of the Company that involves risk and uncertainties. Risks and uncertainties of the Company will be detailed from time to time in the Company's periodic reports to be filed with the Securities and Exchange Commission. Contact Advanced Optics Electronics, Inc. at (505) 797-7878 or for further information visit their web site at www.adot.org.